Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Feb;53(1):1-6.
doi: 10.1007/s13139-019-00573-2. Epub 2019 Jan 15.

Nuclear Theranostics in Asia: In vivo Companion Diagnostics

Dong Soo Lee  1 , Gi Jeong Cheon  1
Affiliations
Editorial

Nuclear Theranostics in Asia: In vivo Companion Diagnostics

Dong Soo Lee et al. Nucl Med Mol Imaging. 2019 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical StandardsDong Soo Lee and Gi Jeong Cheon declare that there is no conflict of interest.

Figures

Fig. 1
Fig. 1
Best examples of nuclear medicine procedures used as in vivo companion diagnostics. Among the non-communicable diseases, brain perfusion SPECT helped choose stent insertion or bypass operation for carotid/cerebral artery stenosis/obstruction and myocardial SPECT predicted major adverse cardiac events (cardiac death and acute myocardial infarction) and helped choose needs of stenting/bypass operation for coronary artery diseases. Anatomical imaging with angiography was used to define the diseases and functional imaging with SPECT was used to define the functional significance
Fig. 2
Fig. 2
Summary of theranostics in cancer by nuclear theranostic procedures
Fig. 3
Fig. 3
Theranostic use of imaging in the successfully treated cases by nuclear medicine. a Theranostic triage of patients with neuroendocrine tumors. Ga-68 DOTATATE PET is used to choose patients needing Lu-177 DOTATATE treatment. b A case who received Lu-177 DOTATATE treatment and contemporaneous SPECT imaging on the first treatment and the follow-up treatment
See this image and copyright information in PMC

References

    1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61. doi: 10.1126/science.aaa8172. - DOI - PubMed
    1. Food and Drug Administration of USA. Principles for codevelopment of an in vitro companion diagnostic device with a therapeutic product. 2016 https://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrod.... Accessed 8 Dec 2018.
    1. Korean Ministry of Food and Drug Safety. Guideline for approval of medicines associated with companion diagnostic devices. 2018 http://www.nifds.go.kr/brd/m_15/view.do?seq=12442. Accessed 8 Dec 2018.
    1. Food and Drug Administration of USA. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). 2018.
    1. Prasad V. The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab. JAMA Intern Med. 2014;174:1887–1888. doi: 10.1001/jamainternmed.2014.5756. - DOI - PubMed

Publication types

LinkOut - more resources